Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

Historic redlining, modern neighborhood structures, and mortality in children, adolescents, and young adults with cancer.

  • Read more about Historic redlining, modern neighborhood structures, and mortality in children, adolescents, and young adults with cancer.

Feasibility and acceptability of social determinants of health data collection in the context of a Children’s Oncology Group trial.

  • Read more about Feasibility and acceptability of social determinants of health data collection in the context of a Children’s Oncology Group trial.

Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel.

  • Read more about Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel.

Addition of chemo-immunotherapy to standard induction chemotherapy for high-risk neuroblastoma.

  • Read more about Addition of chemo-immunotherapy to standard induction chemotherapy for high-risk neuroblastoma.

Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).

  • Read more about Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).

Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.

  • Read more about Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.

Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.

  • Read more about Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.

Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.

  • Read more about Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.

Phase I trial of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.

  • Read more about Phase I trial of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.

Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

  • Read more about Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

Pagination

  • Page 1
  • Next page ››
Subscribe to Journal of Clinical Oncology

Pediatrics Home

MAKE A GIFT

© 2022 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                              Accessibility  Privacy Policy  Terms of Use  A-Z Website List